---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-23-000025"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:43:26.043322+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Altimmune reports Q1 net loss $20.1M; pemvidutide NASH trial initiation mid-2023

## Summary
- Net loss of $20.1M ($0.40/share) vs $19.4M ($0.44/share) in Q1 2022; R&D expenses $17.2M.
- Cash $165.8M at March 31, 2023; MOMENTUM obesity trial 48-week top-line results expected Q4 2023.
- Pemvidutide 24-week data: 10.7% (2.4mg) and 9.4% (1.8mg) mean weight loss; ~50% achieved ≥10% loss.
- IMPACT Phase 2b NASH trial (~190 subjects) to start mid-2023; top-line results expected Q1 2025.
- HepTcell Phase 2 CHB trial fully enrolled (~80 subjects); top-line results expected Q1 2024.

## SEC filing metadata
- accession: 0001326190-23-000025
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000025/0001326190-23-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000025/alt-20230511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-23-000025
- JSON: https://secwatch.observer/filing/0001326190-23-000025.json
- Plain text: https://secwatch.observer/filing/0001326190-23-000025.txt

## Key facts
- Earnings Releases
  Altimmune, Inc. reported three months ended March 31, 2023 results: net income $20.1 million, EPS $0.40 net loss per share.
  - Period: three months ended March 31, 2023
  - Net income: $20.1 million
  - EPS: $0.40 net loss per share
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2023 was $20.1 million, or $0.40 net loss per share, compared to a net loss of $19.4 million, or $0.44 net loss per share, in the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000025/0001326190-23-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.